Advanced

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

Janelidze, Shorena LU ; Stomrud, Erik LU ; Smith, Ruben LU ; Palmqvist, Sebastian LU ; Mattsson, Niklas LU ; Airey, David C. ; Proctor, Nicholas K. ; Chai, Xiyun ; Shcherbinin, Sergey and Sims, John R. , et al. (2020) In Nature Communications 11(1).
Abstract

Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD), reflecting abnormal tau metabolism in the brain. Here we investigate the performance of CSF p-tau217 as a biomarker of AD in comparison to p-tau181. In the Swedish BioFINDER cohort (n = 194), p-tau217 shows stronger correlations with the tau positron emission tomography (PET) tracer [18F]flortaucipir, and more accurately identifies individuals with abnormally increased [18F]flortaucipir retention. Furthermore, longitudinal increases in p-tau217 are higher compared to p-tau181 and better correlate with [18F]flortaucipir uptake. P-tau217 correlates better than p-tau181 with CSF... (More)

Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD), reflecting abnormal tau metabolism in the brain. Here we investigate the performance of CSF p-tau217 as a biomarker of AD in comparison to p-tau181. In the Swedish BioFINDER cohort (n = 194), p-tau217 shows stronger correlations with the tau positron emission tomography (PET) tracer [18F]flortaucipir, and more accurately identifies individuals with abnormally increased [18F]flortaucipir retention. Furthermore, longitudinal increases in p-tau217 are higher compared to p-tau181 and better correlate with [18F]flortaucipir uptake. P-tau217 correlates better than p-tau181 with CSF and PET measures of neocortical amyloid-β burden and more accurately distinguishes AD dementia from non-AD neurodegenerative disorders. Higher correlations between p-tau217 and [18F]flortaucipir are corroborated in an independent EXPEDITION3 trial cohort (n = 32). The main results are validated using a different p-tau217 immunoassay. These findings suggest that p-tau217 might be more useful than p-tau181 in the diagnostic work up of AD.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Nature Communications
volume
11
issue
1
article number
1683
publisher
Nature Publishing Group
external identifiers
  • pmid:32246036
  • scopus:85083041974
ISSN
2041-1723
DOI
10.1038/s41467-020-15436-0
language
English
LU publication?
yes
id
0ab1fa92-d2ad-482f-aaaf-a7b2dc0add12
date added to LUP
2020-05-25 12:57:29
date last changed
2020-10-27 03:35:33
@article{0ab1fa92-d2ad-482f-aaaf-a7b2dc0add12,
  abstract     = {<p>Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD), reflecting abnormal tau metabolism in the brain. Here we investigate the performance of CSF p-tau217 as a biomarker of AD in comparison to p-tau181. In the Swedish BioFINDER cohort (n = 194), p-tau217 shows stronger correlations with the tau positron emission tomography (PET) tracer [<sup>18</sup>F]flortaucipir, and more accurately identifies individuals with abnormally increased [<sup>18</sup>F]flortaucipir retention. Furthermore, longitudinal increases in p-tau217 are higher compared to p-tau181 and better correlate with [<sup>18</sup>F]flortaucipir uptake. P-tau217 correlates better than p-tau181 with CSF and PET measures of neocortical amyloid-β burden and more accurately distinguishes AD dementia from non-AD neurodegenerative disorders. Higher correlations between p-tau217 and [<sup>18</sup>F]flortaucipir are corroborated in an independent EXPEDITION3 trial cohort (n = 32). The main results are validated using a different p-tau217 immunoassay. These findings suggest that p-tau217 might be more useful than p-tau181 in the diagnostic work up of AD.</p>},
  author       = {Janelidze, Shorena and Stomrud, Erik and Smith, Ruben and Palmqvist, Sebastian and Mattsson, Niklas and Airey, David C. and Proctor, Nicholas K. and Chai, Xiyun and Shcherbinin, Sergey and Sims, John R. and Triana-Baltzer, Gallen and Theunis, Clara and Slemmon, Randy and Mercken, Marc and Kolb, Hartmuth and Dage, Jeffrey L. and Hansson, Oskar},
  issn         = {2041-1723},
  language     = {eng},
  number       = {1},
  publisher    = {Nature Publishing Group},
  series       = {Nature Communications},
  title        = {Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease},
  url          = {http://dx.doi.org/10.1038/s41467-020-15436-0},
  doi          = {10.1038/s41467-020-15436-0},
  volume       = {11},
  year         = {2020},
}